The BRAFV600E mutation is the most common BRAF mutation in primary brain tumors and has been found in adult and pediatric gliomas, Dabrafenib, an effective BRAFV600 inhibitor, has shown therapeutic effects on BRAFV600-mutated pediatric gliomas [16]. Here, BRAF is linked to glioma.